
A study published last Sunday in the New England Journal of Medicine is receiving ample response from omega-3 industry organizations. Using a population cohort of nearly 5,000 people who supplemented with omega-3-enriched margerines for 40 months, researchers behind the study concluded that 'Low doses of omega-3 fatty acids did not significantly reduce the rates of cardiovascular end points.' This was determined to be the case with eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), and alpha-linolenic acid (ALA).

